Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Nanomedicine. 2013 Nov 22;10(3):571–578. doi: 10.1016/j.nano.2013.11.007

Figure 5.

Figure 5

Unimmunized mice (n=6) or animals from groups immunized with TrxA::PA44-OVA (n=6) or TrxA::PA44-OVA@CaP (n=6) were challenged with WSN-OVA 8 months post-vaccination. (A) Spleens were excised from three mice in each group after 7 days. Single cell suspensions were analyzed for OVA-specific CD8+ T cells by flow cytometry using anti-CD44 antibody and H2Kb-restricted SIINFEKL tetramer. (B) Quantification of H2Kb-restricted SIINFEKL tetramer binding CD8+ T cells from the spleen of the mice. (C) The remaining 3 animals in each cohort were monitored for weight loss.